Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations
Advertisement

Related Content

Final AER Guidance Requires Full Address, Recommends Prefatory Language
Final Guidance For Reporting Adverse Events Gets Serious On Definitions
The "Why" Behind Enforcement Is The Key FDA Transparency Issue
Zicam Case Shows FDA Takes Defining Adverse Events Seriously
Supplement Industry Wants Answers From FDA Transparency Task Force
Hydroxycut Recall Sheds Light On Pros And Cons Of AER System
FDA Estimates Dollar Costs For Adverse Event Labeling But Doubts Persist
Supplements Shielded From Spread Of Peanut Butter-Like Problems – Trades
Return To Sender, Industry Groups Say Of AER Address Guidance
Return To Sender, Industry Groups Say Of AER Address Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS102399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel